335 related articles for article (PubMed ID: 12194988)
1. Genetics of myeloid leukemias.
Kelly LM; Gilliland DG
Annu Rev Genomics Hum Genet; 2002; 3():179-98. PubMed ID: 12194988
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetics of human leukemias: new insights into therapy.
Gilliland DG
Semin Hematol; 2002 Oct; 39(4 Suppl 3):6-11. PubMed ID: 12447846
[TBL] [Abstract][Full Text] [Related]
3. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
4. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
[TBL] [Abstract][Full Text] [Related]
5. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
Robinson LJ; Xue J; Corey SJ
Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
[TBL] [Abstract][Full Text] [Related]
6. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanisms in leukemogenesis].
Mitani K
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1107-12. PubMed ID: 12145988
[TBL] [Abstract][Full Text] [Related]
10. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Cuenco GM; Ren R
Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
[TBL] [Abstract][Full Text] [Related]
11. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
12. The role of FLT3 in haematopoietic malignancies.
Stirewalt DL; Radich JP
Nat Rev Cancer; 2003 Sep; 3(9):650-65. PubMed ID: 12951584
[TBL] [Abstract][Full Text] [Related]
13. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
14. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
16. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
17. The molecular basis of leukemia.
Gilliland DG; Jordan CT; Felix CA
Hematology Am Soc Hematol Educ Program; 2004; ():80-97. PubMed ID: 15561678
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
Yanada M; Matsuo K; Suzuki T; Kiyoi H; Naoe T
Leukemia; 2005 Aug; 19(8):1345-9. PubMed ID: 15959528
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
[TBL] [Abstract][Full Text] [Related]
20. FLT3: ITDoes matter in leukemia.
Levis M; Small D
Leukemia; 2003 Sep; 17(9):1738-52. PubMed ID: 12970773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
